Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Palo Alto Networks (NasdaqGS:PANW) from Buy to Neutral. Analyst Price Forecast Suggests 22.11% Upside As of December 23, 2024, ...

AvidXchange Holdings Inc (AVDX) stock saw a decline, ending the day at $9.8 which represents a decrease of $-0.32 or -3.16% from the prior close of $10.12. The stock opened at $10.06 and touched a low ...

Globus Medical (GMED – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Vik Chopra ...

After a busy 2024, experts called out competition in soft tissue robotics, uncertainty from a Trump White House and continued ...

“In 2025, the energy sector will be less about barrels of oil and more about...billions of cubic feet of natural gas demand in 2025 and beyond as the technology sector intersects with the energy ...

BofA Securities has recently resumed On Holding AG (ONON) stock to Buy rating, as announced on January 7, 2025, according to Finviz. Earlier, on December 18, 2024, Citigroup had initiated the stock to ...

Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) has earned an average recommendation of “Hold” from the seven ...